Emerging Trends in Non-Alcoholic Fatty Liver Disease

Event Date: March 18 - 19, 2017

Event Location: Hyatt Regency Washington on Capitol Hill, 400 New Jersey Avenue, NW, Washington, DC 20001

NAFLD M30 Apoptosis Necrosis ELISA Assay Test Kit NAFLD M30 Apoptosis Necrosis ELISA Assay Test Kit NAFLD M30 Apoptosis Necrosis ELISA Assay Test Kit

Diapharma will be attending the Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease this year. Please click here to schedule a meeting with us or email us directly.


The 2017 Emerging Trends Conference will spearhead a development strategy to disseminate new knowledge in NAFLD. Major advances in the epidemiology, natural history, pathogenesis and diagnostic modalities have been uncovered. By facilitating new and exciting translational and therapeutic research in NAFLD, collaborations among clinicians, industry, academic institutions, and public health agencies will be well equipped to deal with this epidemic.liver assay test kit


The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists to bring together those who had contributed to the field of hepatology.


Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of chronic liver disease requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which however may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality.

There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design.

Emerging Trends Conference | AASLD | Twitter | Facebook | YouTube | Hyatt Regency Washington on Capitol Hill | Reservations